This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Combined Approach to Resection of Glioblastoma (GBM) by 5-Aminolevulinic Acid (5-ALA) and Intraoperative Magnetic Resonance Imaging (MRI)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2010 by University of Zurich.
Recruitment status was:  Recruiting
Information provided by:
University of Zurich Identifier:
First received: April 13, 2010
Last updated: October 21, 2010
Last verified: February 2010

In the treatment of glioblastoma (GBM) neurosurgical resection of the tumor is usually considered a a first step of effective therapy. Radical resection of the tumor is highly beneficial to the patient as measured in progression-free survival and overall survival. At the same time eloquent areas of the brain have to remain intact to preserve quality of life.

Both 5-ALA fluorescence and intraoperative MRI are used for intraoperative marking of tumor tissue and thereby to improve precision of GBM-Resection.

We now study whether the combination of 5-ALA fluorescence and intraoperative MRI increases the number of sites where tumor tissue can be detected.

- Trial with surgical intervention

Condition Intervention
Glioblastoma Procedure: diagnostic 5-ALA and MRI for tumor resection

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Combined Approach to GBM-resection by 5-ALA and Intraoperative MRI

Resource links provided by NLM:

Further study details as provided by University of Zurich:

Biospecimen Retention:   Samples Without DNA
tumor samples for pathophysiology

Estimated Enrollment: 40
Study Start Date: August 2009
Estimated Study Completion Date: December 2011
Estimated Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Procedure: diagnostic 5-ALA and MRI for tumor resection
    diagnostic 5-ALA and MRI for tumor resection
Detailed Description:
Precision of GBM-Resection Intraoperative marking of tumor tissue Combination of 5-ALA fluorescence and intraoperative MRI

Ages Eligible for Study:   20 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
patients with Glioblastoma multiforme (GBM)

Inclusion criteria:

  • patients with Glioblastoma multiforme (GBM)
  • no other tumor types or metastases

Exclusion criteria:

  • Allergy against 5-ALA or Porphyrin
  • Porphyria
  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01208909

Contact: René L. Bernays, MD +41 (0)44 255 11 11

UniversitätsSpital Zürich Recruiting
Zurich, Switzerland
Contact: René L Bernays, MD    +41 44 25 ext 5111      
Sponsors and Collaborators
University of Zurich
Study Director: René L Bernays, MD UniversitaetsSpital Zuerich
  More Information

Responsible Party: Dr. R. L. Bernays, University of Zurich Identifier: NCT01208909     History of Changes
Other Study ID Numbers: ZU-XYZ-002
Study First Received: April 13, 2010
Last Updated: October 21, 2010

Additional relevant MeSH terms:
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Aminolevulinic Acid
Photosensitizing Agents
Dermatologic Agents processed this record on September 20, 2017